Transforming CLTI Treatment: Giving No-Option Patients New Options

“We’re talking about completely flipping the tables from almost everybody getting an amputation to only a minority of patients getting an amputation by the time you follow them for one year.” – Peter Schneider, MD

Medtech executive Dan Rose, CEO of LimFlow, and his clinical investigator, renowned vascular surgeon Peter Schneider, MD join Joe Mullings, Chairman of the Board for TMG360 Media, to discuss promising early data that suggests the current standard for treating Chronic Limb-Threatening Ischemia (CLTI) is undergoing a transformation.

Between CMS naming only four procedural categories as non-elective: trauma, transplant, emerging cardiac and limb salvage, and patients continuing to enroll in the ongoing pivotal trial despite the perceived risk, Rose and Schneider share how the COVID-19 pandemic has fueled this transformation.

By triangulating clinical data, market development, and input from physicians, the CLI subject-matter-experts explain how they are making the procedure easier, faster, and simpler. 

As populations continue to age and the rate of chronic diseases such as diabetes, obesity, and renal disease continue to increase, the treatable market for no-option Percutaneous Deep Venous Arterialization (pDVA) is growing. In fact, there were 330,000 new no-option pDVA patients projected in the last year alone. All of which is significantly expanding the PAD market and supercharging BTK growth, representing a potential $1.3 Billion of the estimated $3 Billion US Peripheral Vascular market. 

Today, LimFlow is part of a training session at LINC 2021 to discuss the unmet need, the advancement in treatment options, and what the future holds for CLI.

Learn how LimFlow is giving new hope to no-hope CLTI patients in the interview below.